The assay is fast and simple and has already shown clinical utility, although its interpretation may be limited by reference ...

(Nasdaq: CTKB) announced today that its Cytek ® Muse ® Micro cell analyzer has been named Drug Discovery Solution of the Year in the 2025 BioTech Breakthrough Awards. The annual program, conducted by ...

Patients with 15-day MRD less than 10% blasts fared better than those with 10% or greater, even if they had other high-risk factors.

Minimal residual disease (MRD)-guided retreatment with anti-CD20 antibodies effectively lowers MRD levels and delays clinical relapse in patients with high-risk chronic lymphocytic leukemia (CLL), ...

Invited presentation followed by panel discussion on the next wave of innovation in immunotherapy of cancer: Paul Peter Tak, M.D., Ph.D., ...

BD rides high on product demand across segments, but fourth-quarter fiscal 2025 results may face pressure from global market ...

INDICATION AUCATZYL ® is a CD19-directed genetically modified autologous T cell immunotherapy indicated for the treatment of adult patients with relapsed or refractory B-cell precursor acute ...

Akeso, Inc. (HKEX: 9926.HK) published the preclinical research data for its novel antagonistic monoclonal antibody targeting IL-1RAP, AK135, at the 40th Annual Meeting of the Society for Immunotherapy ...

A 70-year-old man presented to Tufts emergency department with a 2-day history of left eye redness and periorbital swelling ...

Pregnancy and breastfeeding leave behind long-lived CD8+ T cells that can persist for decades, providing lasting immune surveillance in breast tissue.

Urolithin A, a natural postbiotic known to trigger mitophagy, rejuvenated key immune cell functions in healthy middle-aged ...